达美康缓释片联合诺和锐30治疗2型糖尿病的初步研究

Preliminary study of type 2 diabetes, treatment with glielazide sustained-release tablets and aspart 30

目的探讨达美康缓释片联合诺和锐30对2型糖尿病的治疗效果。方法将入选患者随机分成达美康缓释片加诺和锐30治疗组和二甲双胍联合诺和灵30R对照组，疗程为6个月，药物治疗前和治疗后1、3、6月末抽静脉血查空腹血糖（FBG）、餐后2h血糖（PG2h）、糖化血红蛋白（HbAlc）、TG、TC、C-P及餐后2hC-P（C—P2h）。结果两组治疗前后对比差异均有统计学意义，两组治疗下降值对比除餐后2h血糖外其余差异无统计学意义。结论对于非重度肥胖2型糖尿病患者口服降糖药物疗效欠佳或初发糖尿病患者空腹血糖较高时可以选用达美康缓释片加诺和锐30治疗。

Objective To explore the therapy of gliclazide sustained-release tablets and aspart 30 to cure type 2 diabetes patients. Methods Selected patients were randomly divided into gliclazide sustained-re- lease tablets （ ＋ aspart 30 ） treatment group and mefformin （ ＋ Novolin 30R） control group, the course of treat- ment 6 monthsThe baseline fasting blood glucose,2-hour postprandial blood glucose, glyeosylated hemoglobin, total cholesterol, triglyeeride, fasting serum C-P and 2-hour postprandial serum C-P were inspected. Results In the two groups before and after treatment, differences was statistically significant in fasting blood glucose ,2-hour postprandial blood glucose, glyeosylated hemoglobin, total cholesterol, triglyceride, fasting serum C-P and 2-hour postprandial serum C-P. At the same time changes were not statistically significant between the two groups, except in 2-hour postprandial blood glucose. Conclusion Patients can be treated with gliclazide sustained-release tablets and aspart 30 for non-severely obese type 2 diabetic patients when the treat with oral hypoglycemic drug is ineffective for initial onset diabetes with the fasting blood glucose is high.